New US trade tariffs on pharmaceutical imports from the EU have raised concerns within the biopharma industry amid ongoing uncertainties around drug pricing and regulatory climates. European pharma leaders such as AstraZeneca and GSK expressed measured confidence, noting ongoing capacity expansions and supply chain adjustments to mitigate tariff impacts. Concurrently, companies like Syncona are revising strategies to navigate capital access challenges caused by trade policy and pricing pressures. Industry stakeholders remain watchful as tariff frameworks and Medicare negotiations evolve.